LA Society for the Arts in Healthcare Event Coverage of a networking party at the home of Lynn and Dr. Ed Crandall involving the USC Institute for Genetic Medicine Art Gallery which is a member of the Society for the Arts in HealthcareFrom:harrisfromparisViews:133 0ratingsTime:03:37More inEducation View post: LA Society for the Arts in Healthcare Event - Video … Continue reading →

USC Institute for Genetic Medicine Art Show From:SOSMentorsViews:26 1ratingsTime:03:01More inEducation Read the rest here: USC Institute for Genetic Medicine Art Show - Video … Continue reading →

Dolan Lecture Series 2000 - Ronald G. Crystal, MD Therapy for the New Millennium: Using Genetic Medicine to Regenerate Diseased OrgansFrom:DolanLectureSeriesViews:6 0ratingsTime:01:00:37More inPeople Blogs Excerpt from: Dolan Lecture Series 2000 - Ronald G. Crystal, MD - Video … Continue reading →

Implementation of Genetic Medicine Programs: Laboratories - Stephen Chanok June 28-29, 2012 - Sequencing in Cohort Studies and Large Sample Collections More: http://www.genome.govFrom:GenomeTVViews:29 1ratingsTime:20:54More inScience Technology Visit link: Implementation of Genetic Medicine Programs: Laboratories - Stephen Chanok - Video … Continue reading →

Shane McKee: Showreel 1 Never let Shane out in Israel with an iPhone. This is a showreel I put together for PastPreservers, purely from footage hand-shot with an iPhone, and some photos audio patched in. I'm a Clinical Geneticist (doctor in Genetic Medicine), so that's the area I can claim proper expertise in, but my other science communication interests include: the Middle East (ancient and modern), Egyptology, General Science, the Religion-Science debate, Human Origins and lots more.From:Shane McKeeViews:47 1ratingsTime:04:54More inEducation Go here to see the original: Shane McKee: Showreel 1 - Video … Continue reading →

3D Printing: The Future of Manufacturing Alex Daley of Casey Research discusses the 3D printing revolution and its impact on the future of manufacturing. He also sheds light on curing cancer, biological medicine, genetic medicine, digital content, computer technology, electronic devices, popular mechanics, the human genome, globalization, monoclonal antibodies, biotechnology and much more. Michael Nuschke of Retirement Singularity discusses the technology and science behind 3D printing 3D manufacturing and how this will impact investors. ****************************************** Original source: Alex Daley Tech Talk -- Casey Research: http://www.youtube.com My blog = http://www.RetirementSingularity.com Facebook = httpFrom:RetireSingularityViews:287 9ratingsTime:09:25More inEducation Go here to see the original: 3D Printing: The Future of Manufacturing - Video … Continue reading →

Richard Morimoto, 2nd International Conference Genetics of Aging and Longevity Richard Morimoto (Northwestern Center for Genetic Medicine, USA) "The stress of misfolded proteins in biology, aging and disease".From:ФондУМАViews:4 0ratingsTime:37:27More inScience Technology See the article here: Richard Morimoto, 2nd International Conference «Genetics of Aging and Longevity» - Video … Continue reading →

Update on Down Syndrome Research: A Collaboration Between DSRTF and NDSS In celebration of October 2012 as Down Syndrome Awareness Month, the National Down Syndrome Society and the Down Syndrome Research and Treatment Foundation collaborated with Dr. Roger Reeves to update the Down syndrome community on the status of Down syndrome cognition research. Dr. Roger Reeves is Professor in the Department of Physiology and a Core Faculty Member of the McKusick-Nathans Institute for Genetic Medicine at the Johns Hopkins University School of Medicine. He is noted for his contributions to the study of genes using animal models to understand to identify genetic modifiers that contribute to more or less severe presentation of Down syndrome. Slides from the presentation are available at http://www.ndss.orgFrom:NDSSorgViews:263 0ratingsTime:58:16More inNonprofits Activism The rest is here: Update on Down Syndrome Research: A Collaboration Between DSRTF and NDSS - Video … Continue reading →

ScienceDaily (Oct. 23, 2012) Although placebos have played a critical role in medicine and clinical research for more than 70 years, it has been a mystery why these inactive treatments help to alleviate symptoms in some patients -- and not others. Now researchers have for the first time identified genetic differences between placebo responders and non-responders, providing an important new clue to what has come to be known as "the placebo effect." Led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School (HMS), the new findings demonstrate that genetic differences that account for variations in the brain's dopamine levels help to determine the extent of a person's placebo response, a discovery that not only has important implications for patient care, but could also prove to be of significant benefit to researchers in designing and conducting clinical trials to help determine a drug's effectiveness. The findings appear in the October 23 issue of PLOS ONE. "There has been increasing evidence that the neurotransmitter dopamine is activated when people anticipate and respond to placebos, " explains the study's first author Kathryn Hall, PhD, a research fellow in the Division of General Medicine and Primary Care and member of … Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, announced today that the California Institute for Regenerative Medicine (CIRM) has approved an award to the company for $9.3 million for the first round of its new Strategic Partnership Awards initiative. The award is to support a Phase 1/2 study to evaluate the safety and efficacy of LentiGlobin, the companys development-stage program for the treatment of beta-thalassemia, which will be initiated in the United States in 2013. We are very encouraged by the clinical data generated to date demonstrating the potential of LentiGlobin as a one-time transformative gene therapy for patients with beta-thalassemia, said David Davidson, M.D., chief medical officer, bluebird bio. bluebird bio has made significant advances in lentiviral vector design, transduction efficiency, and in our manufacturing process, enabling the production of gene-modified products that can be scaled and deployed for many different clinical indications. We are delighted that CIRM has chosen to recognize the importance of this innovative approach for the treatment of one of the most commonly inherited blood disorders, and we are excited to work with CIRM to continue the development of LentiGlobin in the U.S. bluebird bios … Continue reading →